NCT00254384View on ClinicalTrials.gov

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 5, 2005

Primary Completion Date

May 21, 2024

Study Completion Date

May 21, 2024

Conditions
Recurrent Lung Non-Small Cell CarcinomaStage IA Lung Non-Small Cell Carcinoma AJCC v7Stage IB Lung Non-Small Cell Carcinoma AJCC v7Stage IIA Lung Non-Small Cell Carcinoma AJCC v7Stage IIB Lung Non-Small Cell Carcinoma AJCC v7Stage IIIA Lung Non-Small Cell Cancer AJCC v7Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
DRUG

Cisplatin

Given IV

DRUG

Docetaxel

Given IV

DRUG

Erlotinib

Given PO

DRUG

Erlotinib Hydrochloride

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00254384 - Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery | Biotech Hunter | Biotech Hunter